The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IPIG 2025 | Predicting and monitoring for thromboembolism in patients with PNH
Thromboembolism is a significant cause of morbidity and mortality in patients with paroxysmal nocturnal hemoglobinuria (PNH). Yasutaka Ueda, MD, PhD, Osaka University, Suita, Japan, emphasizes the importance of educating patients about the risk of thrombosis and its symptoms, such as abdominal pain or chest pain, in order to promptly identify potential complications. Dr Ueda notes that while biomarkers like D-dimer levels can be monitored, there is currently no established evidence to predict the risk of thromboembolism. This interview took place at the 2nd International PNH Interest Group (IPIG) Conference in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Right, that’s a very important question but sometimes it’s very difficult because some symptoms are not so specific. Well, like abdominal pain, chest pain or neurological findings could be very unique and you can think about thromboembolism. So it’s really important to educate the patients about the risk of thrombosis and the symptoms of thrombosis...
Right, that’s a very important question but sometimes it’s very difficult because some symptoms are not so specific. Well, like abdominal pain, chest pain or neurological findings could be very unique and you can think about thromboembolism. So it’s really important to educate the patients about the risk of thrombosis and the symptoms of thrombosis. Then we could quickly react to the patient’s complaint. Of course, we frequently monitor the D-dimer levels or other biomarkers to try to predict, but actually, there is no solid evidence to predict the risk of thromboembolism.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
